In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

University of Texas MD Anderson Cancer Center

http://www.mdanderson.org/

Latest From University of Texas MD Anderson Cancer Center

Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Deals Coronavirus COVID-19

Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape

The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.

Deals Business Strategies

Novartis’s Capmatinib Shows High Response Rates In NSCLC

The MET inhibitor already pending US FDA approval had good results in patients with brain metastases. Spectrum’s TKI inhibitor poziotinib continues to be studied after Cohort 1 failure.

Clinical Trials Cancer

Tech Transfer Roundup: Universities And Biotechs Continue To Look For Ways To Combat COVID-19

AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.

Deals Coronavirus COVID-19
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register